2,2,3,3-tetramethylcyclopropane carboxamide has been researched along with Inflammation in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chandran, P; Chin, CL; Dart, MJ; Daza, AV; El Kouhen, O; Fan, Y; Fox, GB; Gallagher, ME; Garrison, TR; Grayson, GK; Honore, P; Hooker, BA; Hradil, VP; Hsieh, G; Meyer, MD; Pai, M; Ryther, K; Salyers, AK; Tovcimak, AE; Wensink, EJ; Yao, BB; Zhong, C; Zhu, CZ | 1 |
1 other study(ies) available for 2,2,3,3-tetramethylcyclopropane carboxamide and Inflammation
| Article | Year |
|---|---|
Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and
Topics: Amides; Animals; Cell Line; CHO Cells; Cricetinae; Cricetulus; Cyclopropanes; Dermatologic Surgical Procedures; Hindlimb; Humans; Hyperalgesia; Inflammation; Kidney; Magnetic Resonance Imaging; Male; Pain; Pain, Postoperative; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2009 |